AbbVie and Gubra, a company specialising in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, have entered a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity.

Under the terms of the agreement, AbbVie will lead development and commercialisation activities of GUB014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales. GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. The transaction closure is subject to regulatory approvals and other customary closing conditions.